Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359677 | 0.83 | SMN1; SMN2 (0.48) | — | |
| SCHEMBL22590 | 0.81 | CYP17A1 (0.50) | NAMPTCYP17A1CA1CA12CA9 | |
| SCHEMBL21268384 | 0.80 | CA12 (0.43) | NAMPTCYP17A1HDAC3HDAC1HDAC2 | |
| SCHEMBL775002 | 0.79 | NAMPT (0.56) | NAMPTCYP17A1CA1CA12PSMB8 | |
| SCHEMBL2076593 | 0.78 | L3MBTL1 (0.57) | CA1CA12CA9CA2 | |
| SCHEMBL29029431 | 0.78 | HDAC3 (0.56) | NAMPTCYP17A1HDAC3HDAC1HDAC2 | |
| SCHEMBL2540830 | 0.77 | HPGD (0.55) | — | |
| SCHEMBL1419617 | 0.77 | MAPK1 (0.54) | — | |
| SCHEMBL6655436 | 0.77 | PDK1 (0.44) | — | |
| SCHEMBL13055402 | 0.77 | CYP17A1 (0.59) | NAMPTCYP17A1CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | claimed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | claimed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | claimed |
| CN-105980386-A | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2016-09-28 | — | — | CN | claimed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | claimed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | claimed |
| EP-2970307-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | claimed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | claimed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| CN-103097340-A | Therapeutically active compositions and methods of use thereof | AGIOS PHARMACEUTICALS INC | 2013-05-08 | — | — | CN | claimed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | claimed |
| US-7348348-B2 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | MERCK & CO. INC. (US) | 2008-03-25 | — | — | US | claimed |
| US-20050165072-A1 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | claimed |
| CN-118302204-A | Macrocyclic compounds and diagnostic uses thereof | 詹森生物科技公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118201925-A | Macrocyclic compounds and methods of making the same | 詹森生物科技公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-0429366-B1 | Isoindolone derivatives, their preparation and pharmaceutical compositions containing them | RHONE POULENC SANTE (FR) | 1994-03-16 | — | — | EP | disclosed |
| EP-0430771-A1 | Isoindolone derivatives, their preparation and their use as intermediates for the preparation of substance P antagonists | RHONE-POULENC SANTE (FR) | 1991-06-05 | — | — | EP | disclosed |
| EP-0429366-A1 | Isoindolone derivatives, their preparation and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1991-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165072-A1 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | KCNN1, KCNH1, KCNN2 | NAMPT 1333/4885CYP17A1 4203/4885HDAC3 60/4885 |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | NAMPT 1790/4885CYP17A1 1101/4885HDAC3 46/4885 |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | NAMPT 1864/4885CYP17A1 1761/4885HDAC3 222/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | NAMPT 1790/4885CYP17A1 1101/4885HDAC3 46/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | NAMPT 1864/4885CYP17A1 1761/4885HDAC3 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.